Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2015
At a glance
- Drugs Influenza A virus vaccine H2N3 (Primary) ; Influenza A virus vaccine-H9N2 (Primary) ; Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 14 Dec 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 03 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
- 02 Jan 2013 Actual initiation date (Sep 2012) added as reported by ClinicalTrials.gov record.